Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer

Oncology Research

Volumn 21, Issue 4, 2014, Pages 181-191

  Muñoz, Alberto ^a   Pericay, Carles ^b   García Girón, Carlos ^c   Alonso, Vicente ^d   Dueñas, Rosario ^e   Cirera, Luis ^f   Rivera, Fernando ^g   Falcó, Esther ^h   Bustos, Iñaki Alvarez ⁱ   Salud, Anlonieta ^j  

^a HOSPITAL DE CRUCES   (Spain)

^b Hospital Pure Taulí   (Spain)

^c HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^e Hospital Materno Infantil   (Spain)

^f HOSPITAL MÚTUA DE TERRASSA   (Spain)

^g Hospital Marqués de Valdeeilla   (Spain)

^h HOSPITAL SON LLÀTZER   (Spain)

ⁱ HOSPITAL SAN JORGE   (Spain)

^j HOSPITAL ARNAU DE VILANOVA   (Spain)

more..

Author keywords

Bevacizumab; Capecitabine; Metastatic colorectal cancer pyrighl; Oxaliplatin

Indexed keywords

BEVACIZUMAB; CAPECITABINE; ERLOTINIB; K RAS PROTEIN; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; BLOOD ANALYSIS; CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSESTHESIA; EPISTAXIS; FEMALE; FEVER; FOLLOW UP; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; ISCHEMIC COLITIS; LEUKOPENIA; LIVER RESECTION; LUNG EMBOLISM; LUNG METASTASIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; SIGMOIDECTOMY; STOMATITIS; THERAPY DELAY; THORACOTOMY; URINALYSIS; VENOUS THROMBOEMBOLISM; VOMITING;

EID: 84928629659     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504014X13887748696743     Document Type: Article

References (30)

1. De Gramont, A.; Figcr, A.; Seymour, M; Homerin, M.; Hmissi, A.; Cassidy, J.; Boni, C; Cortes-Funes, H.; Cervantes, A.; Freyer, G.; Papamichael, D.; Le Bail, N.; Louvet, C; Hendler, D.; Dc Brand, F.; Wilson, C; Morvan, F.; Bonetti, A. Leucovorin and fluorouracil wiili or without oxaliplatin as Qrst-line treatment in advanced colorectal cancer. J. Clin, Oncol. 18:2938-2947:2000.
2. Goldberg, R. M; Sargent, D. J.; Morion, R. F.; Fuchs, C. S.; Ramanalhan, R. K.; Williamson, S. K.; Findlay, B. P.; Piloi, H. C; Alberts, S. R. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22:23-30; 2004.
3. Giacchetli, S.; Perpoint, B.; Zidani, R.; Le Bail, N.; Faggiuolo, R.; Focan, C; Chollct, P.; Llory, J. F.; Letourneau, Y.; Coudert, B.; Bertheaut-Cvitkovic, F.; Larregain-Fournier, D.; Le Rol, A.; Walter, S.; Adam, R.; Missel, J. L.; Levi, F. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracilleucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18:136-147; 2000.
4. Goldberg, R. M.; Sargent, D. J.; Morion, R. F.; Fuchs, C. S.; Ramanalhan, R. K.; Williamson, S. K.; Findlay, B. P.; Pilot, H. C; Alberts, S. Randomized controlled trial of reduceddose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. J. Clin. Oncol. 24:3347-3353;2006.
5. Tournigand, C; Cervantes, A.; Figer, A.; Lledo, G.; Flesch, M.; Buyse, M.; Mineur, L.; Carola, E.; Eticnne, P. L.; Rivera, F.; Chirivella, I.; Perez-Slaub, N.; Louvet, C; Andre, T.; Tabah-Fisch, I.; De Gramont, A. OPTIMOXI: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-A GF. RCOR study. J. Clin. Oncol. 24:394-400; 2006.
6. Chibaudel, B.; Maindrault-Goebel, F.; Lledo, G.; Mineur, L.; Andre, T.; Bennamoun, M.; Mabro, M.; Artru, P.; Carola, E.; Flesch, M.; Dupuis, O.; Colin, P.; Larsen, A. K.; Afchain, P.; Tournigand, C; Louvet, C; De Gramont, A. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J. Clin. Oncol. 27:5727-5733;2009.
7. Cohen, E. E.; Davis, D. W.; Karrison, T. G.; Seiwerl, T. Y.; Wong, S. J.; Nattam, S.; Kozloff, M. F.; Clark, J. I.; Yan, D. H.; Liu, W; Pierce, C; Daneey, J. E.; Stenson, K.; Blair, E.; Dekker, A.; Vokes, E. E. Erlolinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: A phase 1/11 study. Lancet Oncol. 10:247-257; 2009.
8. Lubner, S. J.; Mahoncy, M. R.; Kolesar, J. L.; Loconte, N. K.; Kim, G. P.; Pilot, H. C; Philip, P. A.; Picus, J.; Yong, W. P.; Horvath, L.; Van Hazel, G.; Erlichman, C. E.; Holen, K. D. Report of a multicenler phase II trial testing a combination of biweekly bevacizumab and daily erlolinib in palients with unresectable biliary cancer: A phase II Consortium study. J. Clin. Oncol. 28:3491-3497;2010.
9. Thomas, M. B.; Morris, J. S.; Chadha, R.; Iwasaki, M.; Kaur, H.; Lin, E.; Kaseb, A.; Glover, K.; Davila, M.; Abbruzzese, J. Phase II trial of the combination of bevacizumab and erlolinib in patients who have advanced hepatocellular carcinoma. J. Clin. Oncol. 27:843-850; 2009.
10. Dickler. M, N.; Rugo, H. S.; Ebcrle, C. A.; Brogi, E.; Caravelli, J. F.; Panageas, K. S.; Boyd, J.; Ych, B.; Lake, D. E.; Dang, C. T.; Gilewski, T. A.; Bromberg, J. F.; Seidman, A. D.; D'Andrea, G. M.; Moasser, M. M.; Melisko, M.; Park, J. W.; Dancey, J.; Norton, L.; Hudis, C. A. A phase II trial of erlolinib in combination with bevacizumab in patients with metastatic breast cancer. Clin. Cancer Res. 14:7878-7883;2008.
11. Herbst, R. S.; O'Neill, V. J.; Fehrenbacher, L.; Belani, C. P.; Bonomi, P. D.; Hart, L.; Melnyk, O.; Ramies, D.; Lin, M.; Sandler, A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlolinib compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J. Clin. Oncol. 25:4743-4750;2007.
12. Dingemans, A. M.; De Langen, A. J.; Van Den Boogaart, V.; Marcus, J. T.; Backes, W. H.; Schollens, H. T.; Van Tinteren, H.; Hoekstra, O. S.; Pruim, J.; Brans, B.; Thunnissen, F. B.; Smit, E. F.; Groen, H. J. First-line erlolinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: A phase II study including molecular imaging. Ann. Oncol. 22(3):559-566; 2011.
13. Therasse, P.; Arbuck, S. G.; Eisenhauer, E. A.; Wanders, J.; Kaplan, R. S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; Van Oosterom, A. T.; Christian, M. C; Gwylher, S. G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United Stales, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92(3):205-2l6; 2000.
14. Cassidy, J.; Taberncro, J.; Twelves, C; Brunet, R.; Butts, C; Conroy, T; Debraud, F.; Figer, A.; Grossmann, J.; Sawada, N.; Schoffski. P.; Sobrero, A.; Van Culsem, E.; Diaz-Rubio, E. XELOX (capecitabine plus oxaliplatin): Active firstline therapy for palients wilh metastatic colorectal cancer. J. Clin. Oncol. 22:2084-2091;2004.
15. Tabernero, J. A. E.; Gomez, A.; Massuti, B.; Sastre, J.; Abad, A. Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) wilh metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD]). J. Clin. Oncol. 28(Suppl; Abstr 3501):15s; 2010.
16. Koopman, M.; Simkens, L. H. J.; Ten Tije, A. J.; Creemers, G.-J.; Loosveld, O. J. L.; De Jongh, F. E.; Erdkamp, F.; Erjavec, Z.; Van Der Torren, A. M. E.; Van Der Hoeven, J. J. M.; Nieboer, P.; Braun, J. J.; Jansen, R. L.; Haasjes, J. G.; Cats, A.; Wals, J. J.; Mol, L.; Dalesio, O.; Van Tinteren, H.; Puntet, C. J. A. Maintenance treatment with capcciiabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO 3 study of the Dutch Colorectal Cancer Group (DCCG). J. Clin. Oncol. 31(Suppl; Abstr 3502); 2013.
17. Tournigand. C. S. B.; Scheithauer, W.; Louvet, C; Andre, T; Lledo G.; et al. mFOLFOX-bevacizumab or XELOX-bevacizumab then bevacizumab (B) alone or with erlolinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safely analysis of DREAM study. J. Clin. Oncol. 27(Suppl; Abstr 4077):15s; 2009.
18. Hecht, J. R.; Mitchell, E.; Chidiac, T; Scroggin, C; Hagenstad, C; Spigel, D.; Marshall, J.; Cohn, A.; McCollum, D.; Stella, P.; Deeter, R.; Shahin, S.; Amado, R. G. A randomized phase IIIB irial of chemotherapy, bevacizumab, and panitumumah compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27:672-680; 2009.
19. Tol, J.; Koopman, M.; Cats, A.; Rodenburg, C. J.; Creemers, G. J.; Schrama, J. G.; Erdkamp, F. L.; Vos, A. H.; Van Groeningen, C. J.; Sinnigc, H. A.; Richel, D. J.; Voest, E. E.; Dijkstra, J. R.; Vink-Borger, M. E.; Antonini, N. E; Mol, L.; Van Krieken, J. H.; Dalesio, O.; Punt, C. J. Chemotherapy, bevacizumab, and celuximab in metastatic colorectal cancer. N. Engl. J. Med. 360:563-572; 2009.
20. Van Cutsem, E.; Peeters, M.; Siena, S.; Humblet, Y.; Hendlisz, A.; Neyns, B.; Canon, J. L.; Van Laethem, J. L.; Maurel, J.; Richardson, G.; Wolf, M.; Amado, R. G. Openlabel phase III trial of panitumumab plus best supportive care compared wilh best supportive care alone in palients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25:1658-1664;2007.
21. Bokemcyer, C; Bondarenko, I.; Makhson, A.; Harlmann, J. T; Aparicio, J.; De Braud, F.; Donea, S.; Ludwig, H.; Schuch, G.; Slroh, C; Loos, A. H.; Zubel, A.; Koralewski, P. Fluorouracil, leucovorin, and oxaliplatin with and without celuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27:663-671; 2009.
22. Weickhardt, A. J.; Price, T. J.; Chong, G.; Gebski, V; Pavlakis, N.; Johns, T. G.; Azad, A.; Skrinos, E.; Fluck, K.; Dobrovic, A.; Salemi, R.; Scott, A. M.; Mariadason, J. M.; Tebbutt, N. C. Dual targeting of the epidermal growth factor receptor using the combination of celuximab and erlotinib: Preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J. Clin. Oncol. 30(13):1505-12; 2012.
23. Roth, A. D.; Tejpar, S.; Delorenzi, M.; Yan, P.; Fiocca, R.; Klingbiel, D.; Dietrich, D.; Biesmans, B.; Bodoky, G.; Barone, C; Aranda, E.; Nordlinger, B.; Cisar, L.; Labianca, R.; Cunningham, D.; Van Cutsem, E.; Bosnian, F. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol. 28:466-474; 2010.
24. Yokola, T. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med. Chem. 12:163-71; 2012.
25. Zhu, C. Q.; Da Cunha Santos, G.; Ding, K.; Sakurada, A.; Cutz, J. C; Liu, N.; Zhang, T; Marrano, P.; Whitehead, M.; Squire, J. A.; Kamel-Reid, S.; Seymour, L.; Shepherd, F. A.; Tsao, M. S.; National Cancer Institute of Canada Clinical Trials Group Study B. R. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin. Oncol 26:4268-4275;2008.
26. Massarelll, E.; Varella-Garcia, M.; Tang, X.; Xavier, A. C; Ozburn, N. C; Liu, D. D.; Bekele, B. N.; Herbst, R. S.; Wistuha, I. I. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res 13:2890-2896;2007.
27. Eberhard, D. A.; Johnson, B. E.; Amler, L. C; Goddard, A.-D.; Heldcns, S. L.; Herbst, R. S.; Ince, W. L.; Janne, P. A.; Januario, T.; Johnson, D. H.; Klein, P.; Miller, V. A.; Ostland, M.-A.; Ramies, D. A.; Sebisanovic, D.; Stinson, J. A.; Zhang, Y.-R.; Scshagiri, S.; Hillan, K. J. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23:5900-5909;2005.
28. Ainann, J. M.; Lee, J. W.; Roder, H.; Brahmcr, J.; Gonzalez, A.; Schiller, J. H.; Carbonc, D. P. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J. Thoraic Oncol. 5:169-178; 2010.
29. Reinacher-Schick, A. K. S.; Freier, W; Arnold, D; Dietrich, G; Geisslcr, M; et al. Activity of the combination of bevaeizumab (Bev) with capecitahine/irhiolecan (Caplri/Bev) or capecitabine/oxaliplalin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). J. Clin. Oncol 26(Suppl; Abslr 4030); 2008.
30. Hochster, H. S.; Hart, L. L; Ramanalhan, R. K.; Childs, B. H.; Hainsworlh, J. D.; Cohn, A. L.; Wong, L.; Fehrenbaeher, L.; Abubakr, Y.; Sail, M. W.; Schwartzberg, L.; Hedrick, E. Safety and efficacy of oxaliplatin and lluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study. J. Clin. Oncol. 26:3523-3529;2008.